Quantcast

Latest Epidermal growth factor receptor Stories

3eec8da6a58c8dbc8d08e7d2634eff8b1
2009-12-24 07:15:00

The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team of Dana-Farber Cancer Institute scientists to discover a compound capable of halting a common type of drug-resistant lung cancer. In a study to be published in the December 24/31 issue of the journal Nature, the researchers report that non-small cell lung cancers that had become invulnerable to the drugs Iressaâ and Tarcevaâ were stymied by a compound...

2009-12-17 06:00:00

- Therapure Biopharma to perform fill/finish of nimotuzumab - MISSISSAUGA, ON, Dec. 17 /PRNewswire-FirstCall/ - David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of...

2009-12-15 22:16:44

Inhibiting fatty acid synthesis in brain cancer cells may offer a new option to treat about 50 percent of deadly glioblastomas that are driven by amplified signaling of the epidermal growth factor receptor (EGFR), according to a first-of-its-kind study by researchers at UCLA's Jonsson Comprehensive Cancer Center. Rapidly dividing cancer cells require fatty acids for the formation of new membranes. The fatty acids also provide an alternative energy source for the cancer cells, and may be...

2009-12-09 17:41:02

Drug resistant lung cancer cells change their behavior in ways we do not understand to evade treatment, but these events can now be recapitulated and studied in mice Lung cancer is the leading cause of cancer mortality worldwide and lung adenocarcinoma is the most common type. Many cases of lung adenocarcinoma are attributed to a mutation in a gene for the epidermal growth factor receptor (EGFR). Lung cancer with changes in EGFR is initially treatable with a family of chemotherapeutic agents...

2009-12-02 17:45:00

NEW YORK, Dec. 2 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Kinase Inhibitors: Global Markets http://www.reportlinker.com/p0166819/Kinase-Inhibitors-Global-Markets.html Forecasts for the global market, providing data for the years 2005 through 2008, and projections for the market and compound annual growth rates (CAGRs) through 2014 An overview of the market for the kinase inhibitor class of drugs that already are...

2009-11-25 14:59:29

M. D. Anderson-led team connects the dots among three distinct components of cancer development, potentially pointing the way to new therapeutic strategies Two signaling pathways essential to normal human development - the Wnt/Wingless (Wnt) and epidermal growth factor receptor (EGFR) pathways - interact in ways that can promote tumor cell invasion and metastasis, researchers from The University of Texas M. D. Anderson Cancer Center report in the Nov. 25 issue of Molecular Cell. This newly...

2009-11-18 11:51:00

MISSISSAUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that results from a study evaluating nimotuzumab were presented today in a poster at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts. The reported results demonstrate that...

2009-10-16 10:31:20

The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck cancers among others. It is unknown if EGFR and HER2 are overexpressed in advanced biliary tract cancer (BTC) and therefore may serve as therapeutic targets in these cancers. A research article to be...

2009-10-08 11:07:23

UH Case Medical Center study in JCO reinforces focus on personalized treatment for patients based on ethnicity Clinical research out of University Hospitals Case Medical Center has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs. Published online in the Journal of Clinical Oncology, the study by Rom Leidner, MD, and colleagues report that ethnicity plays a...

2009-09-22 07:50:08

Patients with advanced non-small cell lung cancer who are given cetuximab (Erbitux) in addition to chemotherapy are 13% less likely to die than those who receive chemotherapy alone, regardless of which chemotherapy drug cocktail is used, new research finds. They also experience slower disease progression and an increased chance of tumor shrinkage. While a large study last year found that patients lived five weeks longer when the targeted drug cetuximab was added to a particular chemotherapy...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related